Advertisement
Screener

VivoSim Labs, Inc. (VIVS) Proceeds from Notes Payable

2.8 / 5 stars · 68/120 Roast Me

VivoSim Labs, Inc. Proceeds from Notes Payable

VivoSim Labs, Inc. (VIVS) reported Proceeds from Notes Payable of $4.63 million for the 80-month period ending 2013-12-31, per its 10-Q filed 2014-02-06.

Discontinued › Cash Flow › Financing Activities

us-gaap:ProceedsFromNotesPayable · last filed 2014-02-06

  • VivoSim Labs, Inc. proceeds from notes payable for the quarter ending 2011-12-31 was $1.50M.
  • VivoSim Labs, Inc. proceeds from notes payable for the quarter ending 2011-09-30 was $743.80K.
  • VivoSim Labs, Inc. proceeds from notes payable for the quarter ending 2011-06-30 was $138.70K.
  • VivoSim Labs, Inc. proceeds from notes payable for the quarter ending 2011-03-31 was $160.00K.
  • VivoSim Labs, Inc. proceeds from notes payable for fiscal 2011 was $2.54M, a 156.35% increase from fiscal 2010.
  • VivoSim Labs, Inc. proceeds from notes payable for fiscal 2010 was $992.00K.
Period endProceeds from Notes Payable 1 monthProceeds from Notes Payable 1 month as first filedProceeds from Notes Payable 2 monthProceeds from Notes Payable 3 monthProceeds from Notes Payable 6 monthProceeds from Notes Payable 9 monthProceeds from Notes Payable 12 monthProceeds from Notes Payable 24 monthProceeds from Notes Payable 47 monthProceeds from Notes Payable 59 monthProceeds from Notes Payable 62 monthProceeds from Notes Payable 65 monthProceeds from Notes Payable 68 monthProceeds from Notes Payable 71 monthProceeds from Notes Payable 74 monthProceeds from Notes Payable 77 monthProceeds from Notes Payable 80 month
2013-12-31$4.63M
10-Q · filed 2014-02-06
2013-09-30$4.63M
10-Q · filed 2013-11-08
2013-06-30$4.63M
10-Q · filed 2013-08-09
2013-03-31$4.63M
10-KT · filed 2013-05-24
2012-12-31$4.63M
10-K · filed 2013-03-15
2012-09-30$4.63M
10-Q · filed 2012-11-14
2012-06-30$4.63M
10-Q · filed 2012-08-14
2012-03-31$4.63M
10-Q · filed 2012-05-15
2012-02-08$1.50M
10-Q · filed 2013-08-09
$0.00
10-Q · filed 2012-08-14
2011-12-31$1.50M
derived: 10-KT 12 month − 10-Q 9 month · filed 2013-05-24
$9.50K
10-Q · filed 2012-01-17
$2.38M
derived: sum of 3 quarters · filed 2013-05-24
$2.54M
10-KT · filed 2013-05-24
$9.50K
10-Q · filed 2012-01-17
$2.39M
10-KT · filed 2013-05-24
2011-09-30$743.80K
derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-14
$882.50K
derived: sum of 2 quarters · filed 2012-11-14
$1.04M
10-Q · filed 2012-11-14
2011-08-31$740.00K
10-KT · filed 2013-05-24
2011-06-30$138.70K
derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-14
$298.70K
10-Q · filed 2012-08-14
2011-03-31$160.00K
10-Q · filed 2012-05-15
2010-12-31$0.00
10-Q · filed 2012-01-17
$992.00K
10-KT · filed 2013-05-24

Similar stocks

Stock NameCountryMarket CapPE Ratio
WINDTREE THERAPEUTICS INC /DE/ (WINT)United States$0.003B-0.32
Calidi Biotherapeutics, Inc. (CLDI)United States$0.003B
CURIS INC (CRIS)United States$0.002B-0.05
PharmaCyte Biotech, Inc. (PMCB)United States$0.005B
Silexion Therapeutics Corp (SLXN)$0.001B
AIM ImmunoTech Inc. (AIM)United States$0.006B
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ)United States$0.006B
CERO THERAPEUTICS HOLDINGS, INC. (CERO)United States$0.007B
TScan Therapeutics, Inc. (TCRX)United States$0.008B-1.23
Senti Biosciences Holdings, Inc. (SNTI)United States$0.011B-0.70